Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Ning Wang, Jian Shang, Shibo Jiang, et al.
Frontiers in Microbiology (2020) Vol. 11
Open Access | Times Cited: 416

Showing 1-25 of 416 citing articles:

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
Wanbo Tai, Lei He, Xiujuan Zhang, et al.
Cellular and Molecular Immunology (2020) Vol. 17, Iss. 6, pp. 613-620
Open Access | Times Cited: 1696
COVID-19 Vaccine: A comprehensive status report
Simran Kaur, Vandana Gupta
Virus Research (2020) Vol. 288, pp. 198114-198114
Open Access | Times Cited: 850
Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
Luis F. García
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 657
COVID-19 vaccine development and a potential nanomaterial path forward
Matthew D. Shin, Sourabh Shukla, Young Hun Chung, et al.
Nature Nanotechnology (2020) Vol. 15, Iss. 8, pp. 646-655
Open Access | Times Cited: 623
Mucosal vaccines — fortifying the frontiers
Ed C. Lavelle, Ross W. Ward
Nature reviews. Immunology (2021) Vol. 22, Iss. 4, pp. 236-250
Open Access | Times Cited: 485
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
Lianpan Dai, Tianyi Zheng, Kun Xu, et al.
Cell (2020) Vol. 182, Iss. 3, pp. 722-733.e11
Open Access | Times Cited: 480
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past
Vibhuti Kumar Shah, Priyanka Firmal, Aftab Alam, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 449
Coronavirus vaccine development: from SARS and MERS to COVID-19
Yen-Der Li, Wei-Yu Chi, Jun-Han Su, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 428
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
Shilong Yang, Yan Li, Lianpan Dai, et al.
The Lancet Infectious Diseases (2021) Vol. 21, Iss. 8, pp. 1107-1119
Open Access | Times Cited: 419
The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens
Liangwei Duan, Qianqian Zheng, Hongxia Zhang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 403
Human coronaviruses OC43 and HKU1 bind to 9- O -acetylated sialic acids via a conserved receptor-binding site in spike protein domain A
Ruben J. G. Hulswit, Yifei Lang, Mark J. G. Bakkers, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 7, pp. 2681-2690
Open Access | Times Cited: 377
Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2
Sairaj Satarker, Madhavan Nampoothiri
Archives of Medical Research (2020) Vol. 51, Iss. 6, pp. 482-491
Open Access | Times Cited: 376
Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses
Xiancai Ma, Fan Zou, Fei Yu, et al.
Immunity (2020) Vol. 53, Iss. 6, pp. 1315-1330.e9
Open Access | Times Cited: 279
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence
Sayeeda Rahman, Maria Teresa Villagomez Montero, Kherie Rowe, et al.
Expert Review of Clinical Pharmacology (2021) Vol. 14, Iss. 5, pp. 601-621
Open Access | Times Cited: 250
Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates
Yin-Feng Kang, Cong Sun, Zhen Zhuang, et al.
ACS Nano (2021) Vol. 15, Iss. 2, pp. 2738-2752
Open Access | Times Cited: 191
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
Zezhong Liu, Wei Xu, Shuai Xia, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 190
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Vivek P. Chavda, Lalitkumar K. Vora, Anjali Pandya, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2619-2636
Open Access | Times Cited: 188
A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice
Abigail E. Powell, Kaiming Zhang, Mrinmoy Sanyal, et al.
ACS Central Science (2021) Vol. 7, Iss. 1, pp. 183-199
Open Access | Times Cited: 169
Peptide and peptide-based inhibitors of SARS-CoV-2 entry
Desirée Schütz, Yasser B. Ruiz‐Blanco, Jan Münch, et al.
Advanced Drug Delivery Reviews (2020) Vol. 167, pp. 47-65
Open Access | Times Cited: 167
Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2
Asif Shajahan, Stephanie Archer‐Hartmann, Nitin T. Supekar, et al.
Glycobiology (2020) Vol. 31, Iss. 4, pp. 410-424
Open Access | Times Cited: 154
JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy
Sairaj Satarker, Antriya Annie Tom, Roshitha Ann Shaji, et al.
Postgraduate Medicine (2020) Vol. 133, Iss. 5, pp. 489-507
Open Access | Times Cited: 147
Serodiagnostics for Severe Acute Respiratory Syndrome–Related Coronavirus 2
Matthew P. Cheng, Cédric P. Yansouni, Nicole E. Basta, et al.
Annals of Internal Medicine (2020) Vol. 173, Iss. 6, pp. 450-460
Open Access | Times Cited: 146
Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics
Caio Perez Gomes, Danilo Euclides Fernandes, Fernanda M. S. Casimiro, et al.
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 144
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
Wanbo Tai, Xiujuan Zhang, Aleksandra Drelich, et al.
Cell Research (2020) Vol. 30, Iss. 10, pp. 932-935
Open Access | Times Cited: 143
Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients
Rasha Itani, Mansour Tobaiqy, Achraf Al Faraj
Theranostics (2020) Vol. 10, Iss. 13, pp. 5932-5942
Open Access | Times Cited: 138
Page 1 - Next Page

Scroll to top